|
Tuesday
|
|
|
|
|
| 09:30-17:30 |
Registration at the conference venue |
|
|
|
|
|
|
|
|
| 19:30-21:30 |
Welcome reception with drinks and light snacks (no dinner) |
|
|
|
|
|
|
|
Wednesday
|
|
|
|
|
| 08:00-08:45 |
Registration at the conference venue |
|
|
|
|
|
|
|
|
| 08:45-09:00 |
Welcome and introduction |
Oscar della Pasqua & Thomas Dorlo
|
|
|
|
|
| 09:00-09:45 |
Keynote lecture |
Rocio Lledo-Garcia & Zinnia Parra Guillen
|
|
|
|
|
| 09:00-09:45 |
Iain Gardner |
Pre-clinical and clinical applications of PBPK models for monoclonal antibodies and other large molecule modalities. |
|
|
|
|
| 09:45-11:15 |
Coffee break, Poster and Software Session I |
|
|
|
|
|
|
|
|
| 11:15-12:15 |
Immunogenicity |
Rocio Lledo-Garcia & Zinnia Parra Guillen
|
|
|
|
|
| 11:15-11:35 |
Hans Peter Grimm |
Learn-and-Confirm in Quantitative Systems Pharmacology: Evaluation of an Immunogenicity Platform |
|
|
|
|
| 11:55-12:15 |
Rory Leisegang |
Immunogenicity dynamics and covariate effects after satralizumab administration predicted with a Hidden Markov Model |
|
|
|
|
| 11:35-11:55 |
Alix Démaris |
Towards understanding anti-infliximab antibody development to predict Crohn’s disease patients' underlying immunogenicity status |
|
|
|
|
| 12:15-13:45 |
Lunch |
|
|
|
|
|
|
|
|
| 13:45-14:25 |
Automatic Model Development |
Gilbert Koch
|
|
|
|
|
| 13:45-14:05 |
Xiaomei Chen |
Development of a tool for fully automatic model development (AMD) |
|
|
|
|
| 14:05-14:25 |
Marc Lavielle |
SAMBA: a new algorithm for automatic construction of nonlinear mixed-effects models. |
|
|
|
|
| 14:25-15:05 |
Model-Informed Precision Dosing |
Stefanie Hennig & Ana Ruiz
|
|
|
|
|
| 14:25-14:45 |
Ron Keizer |
Composite Importance Sampling (CIS) for continuous learning in precision dosing |
|
|
|
|
| 14:45-15:05 |
Benjamin Ribba |
Population model-enhanced reinforcement learning to enable precision dosing: case study with dosing of propofol for sedation |
|
|
|
|
| 15:05-15:10 |
Special Announcement |
|
|
|
|
|
|
|
|
| 15:10-16:40 |
Coffee break, Poster and Software Session II |
|
|
|
|
|
|
|
|
| 16:40-17:20 |
Modelling Other Pharmacological Aspects |
Siv Jönsson & Monica Simeoni
|
|
|
|
|
| 16:40-17:00 |
Orwa Albitar |
Pharmacometric Modeling of Drug Adverse Effects: An Application of Mixture Models in Schizophrenia Spectrum Disorder Patients Treated with Clozapine |
|
|
|
|
| 17:00-17:20 |
Jurgen Langenhorst |
An item response theory model with bounded integer subcomponents to describe the Mayo Clinic subscores in patients with ulcerative colitis |
|
|
|
Thursday
|
|
|
|
|
| 08:30-09:50 |
Lewis Sheiner Student Session |
Al Maloney, Nadia Terranova & Justin Wilkins
|
|
|
|
|
| 08:30-08:55 |
Kamunkhwala Gausi |
A semi-mechanistic model of the population pharmacokinetics and bactericidal activity of high-dose isoniazid against multi-drug-resistant tuberculosis |
|
|
|
|
| 08:55-09:20 |
Yu Fu |
A translational cardiovascular systems model to quantify drug effects on contractility and other hemodynamic variables |
|
|
|
|
| 09:20-09:45 |
Soumya Perinparajah |
Mathematically Modelling CD19+ B Cell Reconstitution After Insult to the Immune System: Paediatric Allogeneic Haematopoietic Stem Cell Transplantation, Rituximab Therapy and Epstein-Barr Viral Reactivation |
|
|
|
|
| 09:45-09:50 |
Presentation Lewis Sheiner Student Session Awards |
|
|
|
|
|
|
|
|
| 09:50-11:20 |
Coffee break, Poster and Software session III |
|
|
|
|
|
|
|
|
| 11:20-12:40 |
Infectious Diseases: SARS-CoV-2 & Tuberculosis |
Thomas Dorlo & France Mentré
|
|
|
|
|
| 11:20-11:40 |
Marie Alexandre |
SARS-CoV-2 mechanistic correlates of protection in non-human primates: insight from modelling response to vaccines. |
|
|
|
|
| 11:40-12:00 |
Alexandra Lavalley-Morelle |
Longitudinal biomarkers predicting death of hospitalized patients for SARS-COV-2 infection: a joint analysis with competing risks |
|
|
|
|
| 12:00-12:20 |
Jacqueline Ernest |
Spatially and temporally resolved diffusion kinetics of bedaquiline and TBAJ-587 in hard-to-treat sites of TB disease |
|
|
|
|
| 12:20-12:40 |
Federico Reali |
PBPK/PD modeling and machine learning approaches to support the development of new drugs and regimens against tuberculosis. |
|
|
|
|
| 12:40-12:45 |
ACoP Announcement |
Anja Henningsson & Ana Ruiz
|
|
|
|
|
| 12:45-14:15 |
Lunch |
|
|
|
|
|
|
|
|
| 14:15-15:00 |
Keynote Lecture |
Oscar Della Pasqua
|
|
|
|
|
| 14:15-15:00 |
Filippo Castiglione |
Modeling biology by agents |
|
|
|
|
| 15:00-16:30 |
Coffee break, Poster, and Software Session IV |
|
|
|
|
|
|
|
|
| 16:30-17:30 |
Stuart Beal Methodology Session |
Emmanuelle Comets & Martin Bergstrand
|
|
|
|
|
| 16:30-16:50 |
Sarah Baklouti |
A methodology to de-shrink Empirical Bayes Estimates |
|
|
|
|
| 16:50-17:10 |
Thomas Bouillon |
Dose selection by covariate assessment on the optimal dose for efficacy – application of machine learning in the context of PKPD |
|
|
|
|
| 17:10-17:30 |
Laura Zwep |
Copula modeling for realistic virtual patient covariate simulation |
|
|
|
|
| 20:00-00:00 |
Social Event |
|
|
|
|
|
|
|
Friday
|
|
|
|
|
| 09:15-10:35 |
Oncology |
Dinesh de Alwis & Rene Bruno
|
|
|
|
|
| 09:15-09:35 |
Zinnia Parra-Guillen |
A physiologically-based pharmacokinetic/pharmacodynamic framework to support clinical development of V937, a novel oncolytic virus |
|
|
|
|
| 09:35-09:55 |
Marion Kerioui |
Joint modelling of individual target lesions and survival to characterize the variability in the response to immunotherapy versus chemotherapy in advanced bladder cancer |
|
|
|
|
| 09:55-10:15 |
Sebastien Benzekry |
Supporting decision making and early prediction of survival for oncology drug development using a pharmacometrics-machine learning based model. |
|
|
|
|
| 10:15-0:35 |
Sarah Lobet |
Target-response relationship of bevacizumab may be more relevant than exposure-response - a target-mediated drug disposition (TMDD) model |
|
|
|
|
| 10:35-10:40 |
Preview of PAGE 2023 |
|
|
|
|
|
|
|
|
| 10:40-11:15 |
Coffee break |
|
|
|
|
|
|
|
|
| 11:15-11:55 |
Real-World Data in Oncology |
Pascal Girard
|
|
|
|
|
| 11:15-11:35 |
Perrine Courlet |
Modelling real-world tumor size dynamics based on electronic health records and image data in advanced melanoma patients receiving immunotherapy |
|
|
|
|
| 11:35-11:55 |
Luca Marzano |
Introducing a novel analytical framework for risk stratification of real-world data with survival and unsupervised machine learning. A small cell lung cancer SCLC study |
|
|
|
|
| 11:55-12:05 |
Closing Remarks |
Oscar Della Pasqua
|
|
|
|
|
| 12:05-12:20 |
Audience input for PAGE 2023 Scientific Programme |
Chair: Thomas Dorlo
|
